Abstract: A wireless sensor probe is used for performing experiments in an interactive laboratory. The probe may include a plurality of sensors for collecting experimental data during an experiment and a transmitter for wirelessly transmitting the collected data to a receiver module. The receiver module is adapted for transferring the data to a computer where a software component may process the data for presentation of the resultant processed data on a display substantially in real-time.

Abstract: A system adapted to process non-karaoke-mode audio content for karaoke presentations is provided. An audio filter module filters a vocal portion from the non-karaoke-mode audio content to obtain filtered audio content. An audio rendering module renders the filtered audio content to generate an audio signal for output of the filtered audio content at an audio output device. A lyric acquiring module acquires lyric information associated with the non-karaoke-mode audio content. A lyric rendering module renders the lyric information to generate a display signal for display of the lyric information such that the lyric information is adapted to be displayed synchronously with the output of the filtered audio content.

Abstract: A system and method assess educational development of a child. Indication of accomplishment by the child of a plurality of tests is entered into the system. A report is generated to indicate educational areas of concern and strength for the child.

Abstract: An education system for educating one or more students wherein the student is presented with a setting and multiple responses. In the application of the system, one or more students provide a verbal response in accord with one of the multiple responses. The student's response is then incorporated into a dialog which is returned to the student.

Abstract: A real-time interactive collaboration system is provided, the system including at least: a collaboration board electronically connected between and amongst an instructor and one or more students, wherein the instructor and students are able to interact in real-time with previously uploaded objects that are part of a learning activity; means for the instructor and students to simultaneously share a predetermined view of the collaboration board; and means for the instructor and students to simultaneously share a portion of a predetermined view of the collaboration board at the discretion of the instructor. Methods of use for the foregoing system are also provided.

Abstract: An organ protectant solution which is intravenously administerable includes a high concentration of cell impermeant molecules which have a charge and/or molecular weight which permit passage across a capillary endothelium and into an interstitial space in said subject but which are too large and/or charged to cross a cell plasma membrane such that said one or more cell impermeant molecules preferentially load into an extracellular fluid compartment can be used to to allow for improved organ harvesting from DCD and brain death donors for transplantation purposes and also can be used extend the “Golden Hour” for traumatic and hemorrhagic shock patients thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.

Abstract: A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analogue thereof; nor-adrenalin; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenalin; and noradrenaline are present in concentrations of each about 0.010 ?M to 0.100 ?M, for example in a ratio of 1:1:1.

Abstract: The present invention pertains to methods of increasing the efficiency of producing a bioproduct. In some embodiments, the method increases the quantity of a bioproduct produced, or decreases bioproduct production time, in a bioreactor cell culture producing the bioproduct, the method comprising, (a) intermittently or continuously analyzing the concentration of one or more nutrients in the bioreactor cell culture; and (b) adding to the bioreactor cell culture additional nutrient media when the concentration of the one or more nutrients is lower than a target value.

Abstract: The present invention relates to a method of rapidly detecting microorganisms using nanoparticles, and more particularly to a method and device of rapidly detecting microorganisms by adding, to the microorganisms to be detected, nanoparticles having immobilized thereon an antibody that binds specifically to the microorganisms to be detected, subjecting the mixture to an immune reaction to form a reaction solution, passing the reaction solution through a microorganism-concentrating film to concentrate the microorganisms, capturing microorganisms, which was immune-reacted with the antibody-immobilized nanoparticles, by a microorganism-capturing filtration membrane, and determining the presence and concentration of the microorganisms.

Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

Abstract: The present invention relates to the detection of infectious agents, more specifically to the detection of murine leukemia viruses and other highly related viruses, including but not limited to ecotropic murine leukemia viruses, xenotropic murine leukemia viruses, and polytropic murine leukemia viruses. Compositions, methods, reaction mixtures and kits are described for the detection of MLV by using in vitro nucleic acid amplification techniques.

Abstract: The present invention provides a universally applicable lysis buffer comprising a chaotropic 5 agent, a reducing agent, and a proteolytic enzyme suitable for processing a wide variety o different sample types, such as different types of bodily samples relevant for the diagnosis o a respiratory disease. Furthermore, the present invention provides the use of a chaotropic agent, a reducing agent, and a proteolytic enzyme for the lysis of a broad spectrum of bodily samples. Moreover, the present invention provides a method for processing bodily samples which is universally applicable to the lysis of a variety of different types of bodily samples. Furthermore, the present invention provides methods for analyzing a bodily sample or for detecting the presence of a pathogen in a bodily sample, preferably, for diagnosing a respiratory disease, such as pneumonia or tuberculosis.

Abstract: A general methodology for the development of highly sensitive and selective sensors that can achieve portable, low-cost and quantitative detection of a broad range of targets using only a personal glucose meter (PGM) is disclosed. The method uses recognition molecules that are specific for a target agent, enzymes that can convert an enzyme substrate into glucose, and PGM. Also provided are sensors, which can include a solid support to which is attached a recognition molecule that permits detection of a target agent, wherein the recognition molecule specifically binds to the target agent in the presence of the target agent but not significantly to other agents as well as an enzyme that can catalyze the conversion of a substance into glucose, wherein the enzyme is attached directly or indirectly to the recognition molecule, and wherein in the presence of the target agent the enzyme can convert the substance into glucose. The disclosed sensors can be part of a lateral flow device.

Abstract: The present teachings provide methods, compositions, and kits for synthesizing and sequencing nucleic acids. In some embodiments, reversible di-nucleotide compounds are employed along with cleaving reactions that remove a label and a blocking moiety. Improved sequencing efficiency is achieved by the rapid polymerase-mediated incorporation of reversible di-nucleotide compounds. In some embodiments, the di-nucleotides do not contain conventional nucleotide triphosphates, but rather employ amino acid phosphoramidate nucleotides (AAPNs).

Abstract: The object of the present invention is to provide a method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease. The object is achieved by the method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease comprising Step (1) of measuring the intracellular SmgGDS expression level of a patient suffering from a cardiovascular disease before and after administration of statin; and Step (2) of determining the type and/or the dose of statin for the patient in reference to the SmgGDS expression level measured in the Step (1).

Abstract: This disclosure describes methods of stimulating macropinocytosis in cancer cells.

Abstract: Particular aspects provide methods and compositions (e.g., gene marker panels) having substantial utility for at least one of diagnosis, identification and classification of colorectal cancer (CRC) (e.g., tumors) relating to distinctive DNA methylation-based subgroups of CRC including CpG island methylator phenotype (CIMP) groups (e.g., CIMP-H and CIMP-L) and non-CIMP groups. Exemplary marker panels include: B3GAT2, FOXL2, KCNK13, RAB31 and SLIT1 (CIMP marker panel); and FAM78A, FSTL1, KCNC1, MYOCD, and SLC6A4 (CIMP-H marker panel). Further aspects relate to genetic mutations, and other epigenetic markers relating to said CRC subgroups that can be used in combination with the gene marker panels for at least one of diagnosis, identification and classification of colorectal cancer (CRC) (e.g., tumors) relating to distinctive CIMP and non-CIMP groups.

Abstract: The present invention provides methods and reagents for diagnosing system lupus erythematosus and for monitoring system lupus erythematosus disease activity in a subject.

Abstract: Soybean Event pDAB9582.814.19.1 comprises genes encoding Cry1F, Cry1Ac (synpro), and PAT, affording insect resistance and herbicide tolerance to soybean crops containing the event, and enabling methods for crop protection and protection of stored products. The invention provides PCR event detection methods.

Abstract: The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence depicted in SEQ ID NOS: 1-4, or a part or the entire sequence of a nucleotide sequence complementary to SEQ ID NOS: 1-4, wherein the oligonucleotide is capable of hybridizing with the nucleotide sequence of Mycobacterium kansasii; a primer and a probe for detecting M. kansasii comprising the oligonucleotide; and a method for detecting M. kansasii using the primer and/or probe. The methods enable the detection of M. kansasii more rapidly and with higher accuracy compared with conventional methods performed by culture. Further, the methods can exclude false positive results for the diagnosis and can also detect and diagnose M. kansasii with higher accuracy compared with methods performed by PCR using conventional primers and/or probes. Still further, the method can quantify M. kansasii cells.

Abstract: The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.

Abstract: In a first aspect, the invention concerns a method for detecting or quantifying DNA methylation at a locus. In one embodiment, a methylation-sensitive endonuclease is formulated together with a polymerase enzyme in an appropriate reaction mixture such that amplification of DNA occurs in a methylation specific manor. Quantitative DNA amplification at selected loci can be used to determine the level of methylation. Kits and reagents for performing such methods are also provided.

Abstract: Provided is a method for diagnosing a bone and joint is disease such as scoliosis. A single nucleotide polymorphism present in region 24 on the long arm of chromosome 10 (region 10q24) is analyzed and the risk of onset of a bone and joint disease and/or the presence or absence of onset of the same are diagnosed on the basis of a result of the analysis.

Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.

Abstract: The present invention provides a real-time nucleic acid amplification method capable of quickly and accurately detecting fluorescence obtained by a nucleic acid amplification method performed in a droplet in a perfect closed system.

Abstract: [Problems] To provide a novel mixture for assaying a target nucleic acid, characterized by enabling a nucleic acid assay while: 1) requiring no step of diluting the target nucleic acid; 2) requiring no procedure of changing a probe concentration depending on a concentration of the target nucleic acid. [Means for Solving Problems] 1) A mixture which comprises one internal standard nucleic acid and two nucleic acid probes labeled with a fluorescent dye; 2) a mixture for measuring Km value which comprises one internal standard nucleic acid having a partial mutation and one nucleic acid probe labeled with a fluorescent dye; 3) a mixture which comprises one internal standard nucleic acid and one double nucleic acid probe labeled with two fluorescent dyes; and a method for assaying a nucleic acid by making use thereof.

Abstract: The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins.

Abstract: The invention relates to a reliable, easy-to-implement non-invasive diagnostic method for detecting early acute kidney injury by measuring the concentration of a biomarker in urine samples, said biomarker being selected from heat shock proteins of the 70 KDa family. More specifically, the invention relates to the identification of heat shock protein 72, whereby said biomarker is identified by means of ELISA and Western blot or by means of the level of RNAm using real-time RT-PCR. The invention helps to solve the current problem that exists in medicine whereby it is not possible to detect acute renal failure in the early stages or the severity of the renal damage in order to treat the patient in a timely manner with an effective therapy.

Abstract: In embodiments there are disclosed culture media, compositions for supplementing culture media, and methods for culturing biological samples. In embodiments the methods are methods for detecting bacteria and in embodiments the bacteria include Salmonella spp and in embodiments include E. coli spp. In embodiments the media and compositions comprise an alkanolamine and a cobalamin compound.

Abstract: Disclosed are compositions and a method for amplification and detection of nucleic acid sequences based on continuous flow thermal gradient PCR.

Abstract: Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. The disclosed methods can be used to diagnosis, prognosis or treat a subject with merosin-deficient congenital muscular dystrophy Type 1A (MDC1A), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral (FHMD), Beckers muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD). Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. In an example, a method of diagnosing or prognosing a subject with muscular dystrophy includes detecting expression of Galectin-1 or Galectin-3 in a sample obtained from the subject at risk of having or having one or more signs or symptoms associated with muscular dystrophy, thereby diagnosing or prognosing the subject with muscular dystrophy. Also provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof.

Abstract: A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency. The invention provides a method for producing induced pluripotent stem cells comprising the step of introducing one or more nucleic acids that facilitate expression of at least one gene selected from the group consisting of NANOG, SOX2, OCT3/4, KLF4, LIN28, and c-MYC into somatic cells.

Abstract: A method for producing cAMP using a chimeric olfactory receptor. The method includes a step of preparing a reaction system comprising a first layer, a lipid bilayer membrane, and a second layer, and a step of supplying a chemical substance which stimulates the chimeric olfactory receptor to the first layer so as to produce the cAMP from ATP. The lipid bilayer membrane includes the chimeric olfactory receptor and adenylate cyclase. The chimeric olfactory receptor penetrates the lipid bilayer membrane. The second layer contains ATP and a G protein. The G protein is placed in the vicinity of one end of the chimeric olfactory receptor. The chimeric olfactory receptor is derived from a mouse olfactory receptor and the N-terminal of the chimeric olfactory receptor is modified with an amino acid sequence.

Abstract: Provided is an assay device and kit for detecting the presence or amount of an analyte of interest.

Abstract: The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.

Abstract: Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein.

Abstract: The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex.

Abstract: In sandwich-type immunoassays that capture a protein analyte between a capture antibody, typically bound to a solid phase, and a detection antibody that is coupled to a reporter group, the number of reporter groups associated with each molecule of analyte is increased by a variety of methods that utilize avidin-biotin-type binding in conjunction with such features as immunological binding to the reporter group on the detection antibody or multiple biotin-avidin-type binding sites.

Abstract: The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite, comprising a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite comprising detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite.

Abstract: A method of determining kinetic parameters for a reversible molecular interaction between a ligand immobilized to a solid support surface and a binding partner to the ligand in solution, comprises sequentially, without intermediate regeneration or renewal of the immobilized ligand, flowing a plurality of fluid volumes containing different known concentrations of the binding partner over the solid support surface, monitoring the momentary amount of binding partner bound to the solid support surface related to time and solution concentration of binding partner and collecting the binding data, and determining the kinetic parameters by globally fitting a predetermined kinetic model for the interaction between the binding partner and the immobilized ligand to the collected binding data, which model allows for mass transport limitation at the solid support surface.

Abstract: The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are associated with the presence of TBI and/or TSI, for monitoring the progress of disease and/or treatment regimens, therapeutics, vaccines, etc., and for assisting clinicians in making treatment decisions.

Abstract: A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group; iv) a modulator; and v) a detector; wherein proximity of the first and second reporter components generates a signal capable of detection by the detector; and wherein the modulator modulates the association of the second interacting group with the third interacting group; such that monitoring the signal generated by proximity of the first and second reporter components by the detector constitutes monitoring the association of the first and third agents.

Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.

Abstract: The diagnosis of a patient with an enteropathic disease or the response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, serum breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

Abstract: An assay apparatus comprising: i) an assay cartridge (52, 53) comprising at least one well (57-62) and a pipette (50) positionable in at least one said well; ii) a holder arranged to received said cartridge; iii) drive means operable to position said pipette in selected wells of said cartridge; iv) a gas pressure applicator couplable to said pipette whereby to cause liquid flow through said membrane; and v) a radiation detector operable to detect radiation from a well of said cartridge of said cartridge or from said pipette.

Abstract: Techniques, apparatus and systems are disclosed for implementing enzyme-logic based diagnosis that uses patterns of multiple markers and biochemical processing of the signal information for reliably identifying cardiac abnormalities and providing a final digital binary answer. In one aspect, a biochemical logic sensing system includes a network of enzyme-biocatalyzed logic gates adapted to receive biomarker input signals and perform an enzyme-biocatalyzed reaction resembling a Boolean logic operation using the received biomarker input signals to generate an output signal of the enzyme-biocatalyzed reaction. A signal processing unit is connected to the network of enzyme-biocatalyzed logic gates. The signal processing unit processes the generated output signal of the enzyme-biocatalyzed reaction and generates a digital binary output having a value of zero or one. The generated digital binary output indicates a type of an injury.

Abstract: The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.

Abstract: Provided herein is a large immuno-sorbent surface area assay (ALISSA) for the rapid and sensitive detection of botulinum neurotoxins (BoNTs) and anthrax toxin. This assay is designed to capture a low number of toxin molecules and to measure their intrinsic protease activity via conversion of a fluorogenic or luminescent substrate. Also provided herein are novel peptides that can be specifically cleaved by BoNT and novel peptides that are resistant to cleavage by BoNT. The combination of these cleavable and control peptides can be used for implementation of an exemplary ALISSA used to specifically detect BoNT enzymatic activity. Furthermore, the ALISSA as described herein may also be used in a column based format for use in a high-throughput system for testing large quantities of samples.

Abstract: Embodiments of the present invention report compositions and methods of analyzing thrombin and plasmin generation in a sample from a subject. In certain embodiments, the methods may comprise introducing at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to thrombin and plasmin generation. In other embodiments, assays disclosed herein concern assessing net hemostatic balance of a subject for diagnostic and/or therapeutic applications.

Abstract: The purpose of the present invention is to provide an FAD-conjugated glucose dehydrogenase that is hard to be inhibited by the inhibitors such as 1,10-phenanthroline. The present invention relates to a modified glucose dehydrogenase (GLD), comprising an amino acid sequence of a wild-type FAD-conjugated glucose dehydrogenase (GLD) represented by SEQ ID NO: 1 having a substitution of at least one amino acid residue selected from the group consisting of amino acid residues at positions 298, 338, 340, 341, 343, 352, 354, 424, 426, 431 and 432, wherein the modified GLD has a reduced susceptibility to an inhibitor, as compared with the wild-type GLD, especially to said modified GLD, which has 40% or more of a relative activity when determined in a system wherein the inhibitor coexists at a final concentration of 1 mM based on an enzymatic activity when determined in a system wherein the inhibitor does not coexist.